Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.
Otto
U
U
Department of Urology, University of Hamburg, West Germany.
Schneider
A W
AW
Conrad
S
S
Klosterhalfen
H
H
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004354:Drug Screening Assays, Antitumor; D005860:Germany, West / Q000453:epidemiology; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D015996:Survival Rate
D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma